This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In an interview with Pharmacy Times at the 2025 Oncology Pharmacists Connect (OPC) meeting, Scott Soefje, PharmD, MBA, BCOP, director of pharmacy at MayoClinic, focused on the evolving role of pharmacists in healthcare, highlighting their increasing presence in outpatient settings to enhance efficiency and patient care.
MayoClinic. RAD 2025: Long-term data on Nemluvio® (nemolizumab) demonstrate its favorable safety profile and sustained and increased improvements in itch and skin lesions in patients with atopic dermatitis up to two years. News release. June 6, 2025. Accessed June 16, 2025. Atopic Dermatitis. News release. May 15, 2024. Ferruggia K.
This act…allowed a pathway for manufacturers to create a ‘copy’ of a licensed patent product to make it cheaper and more discounted,” Soefje, director of pharmacy cancer care services and associate professor of pharmacy at MayoClinic in Rochester, Minnesota, said at the HOPA conference.
Have you observed these immune-related toxicities in your practice, and if so, how are they being managed? All patients should have immunotherapy first. Pharmacy Times : As immunotherapies expand into the solid tumor space, clinicians are reporting cases of ICANS and CRS. It was approved last year.
MayoClinic. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Sirtex Medical’s SIR-Spheres ® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma. News release.
These treatments are already in widespread use across health systems, from MayoClinic’s 9 active and 5 pending to University of California (UC) San Diego Health’s 12 active and 5 under review. At Children’s Hospital of Philadelphia (CHOP), eligible patients can access 12 advanced therapeutics and 8 more in the pipeline.
MayoClinic. FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease. Eli Lilly and Company. News release. July 9, 2025. Accessed July 9, 2025. Alzheimer’s Disease. News release. November 8, 2024. Accessed July 9, 2025. link] Gallagher A. Pharmacy Times.
In an interview with Pharmacy Times , Shaji Kumar, MD, consultant and research chair of the Division of Hematology in the Department of Internal Medicine at MayoClinic, discussed emerging data from the phase 2 RedirecTT-1 study (NCT04586426).
LN is a complication of SLE that occurs when the immune system mistakenly attacks the kidneys, leading to inflammation and potential organ damage. 1 With this approval, belimumab is now accessible for patients and their caregivers at home, rather than needing to travel to a hospital or clinic to receive treatment.
MayoClinic. Akkooi A, Mandala M, Kicinski M, Primary analysis of the EORTC-2139-MG/Columbus-AD trial: A randomized trial of adjuvant encorafenib and binimetinib versus placebo in high-risk stage II melanoma with a BRAF-V600E/K mutation. J Clin Oncol. 43, 2025 (suppl 17; abstr LBA9500). doi:10.1200/JCO.2025.43.17_suppl.LBA9500.
MayoClinic. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. FDA Grants Fast Track Designation for TRE-515 in Combination with Radiation Therapy for the Treatment of Metastatic Castration Resistant Prostate Cancer.
1 "Immunotherapy given neoadjuvantly may not be the appropriate treatment strategy for patients with high fusion,” said Kaushal Parikh, MD, from MayoClinic. “In Mandatory ALK fusion testing should become part of the standard of care to better personalize treatments to a patient’s specific ALK variant.
Following, HR+, HER2- early breast cancer is a common subtype where the cancer cells have estrogen and progesterone receptors but do not have excessive amounts of the HER2 protein, according to MayoClinic. MayoClinic. Clinicaltrials.gov: NCT05306340. Updated April 15, 2025. Accessed June 13, 2025. News release.
MayoClinic. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. JAMA Netw Open. 2025;8(7):e2520011. doi:10.1001/jamanetworkopen.2025.20011 2025.20011 2. Long-term obesity and biological aging in young adults. EuerkAlert!
MayoClinic. " 1 REFERENCES 1. Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System. News release. July 7, 2025. Accessed July 7, 2025. Atrial fibrillation. Accessed July 7, 2025. Boston Scientific. FARAPULSE™ Pulsed Field Ablation System. Accessed July 7, 2025.
The antibody – called lenzilumab – targets colony stimulating factor 2 (CSF2) and granulocyte-macrophage colony stimulating factor (GM-CSF), two cytokines that are linked to the runaway immune response that can result in serious lung damage in COVID-19.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content